Submit your email to push it up the queue
Arriva Medical, LLC, headquartered in the United States, is a leading provider in the healthcare industry, specialising in diabetes management and related medical supplies. Founded in 2008, the company has established a strong presence across various operational regions, focusing on delivering high-quality products and services to patients nationwide. Arriva Medical is renowned for its unique approach to diabetes care, offering a comprehensive range of products, including glucose meters, test strips, and educational resources. Their commitment to patient-centric solutions sets them apart in a competitive market. With a reputation for reliability and innovation, Arriva Medical has achieved significant milestones, positioning itself as a trusted partner for individuals managing diabetes.
How does Arriva Medical, LLC's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Arriva Medical, LLC's score of 49 is higher than 72% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Arriva Medical, LLC, headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Abbott Laboratories, which may influence its climate commitments and reporting practices. While Arriva Medical has not set its own reduction targets or disclosed specific initiatives, it is important to note that any climate commitments or targets would likely be aligned with those of its parent company, Abbott Laboratories. Abbott has established science-based targets for emissions reductions, which may cascade down to Arriva Medical through their corporate relationship. As of now, Arriva Medical's climate strategy appears to be in the early stages, with no specific pledges or initiatives publicly available. The company may benefit from the broader sustainability efforts of Abbott Laboratories, which is actively engaged in reducing its carbon footprint and enhancing its environmental performance.
Access structured emissions data, company-specific emission factors, and source documents
2010 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | 578,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 2 | 691,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 3 | - | - | - | - | - | - | - | - | - | - | - | 00,000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Arriva Medical, LLC is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.